Preclinical in vitro and in vivo models of triple-negative breast cancer provided further promising data regarding reduced tumor growth and metastasis in combinatorial treatment studies with the PDGFRβ-inhibiting aptamer and anti-PD-L1 antibodies [142]. Here, CD274 is linked to triple-negative breast carcinoma.